Arca Biopharma Announces Gencaro Atrial Fibrillation Clinical Data Selected for Presentation at HFSA 2019 Scientific Meeting
ARCA biopharma, Inc. (ABIO)
US:NASDAQ Investor Relations:
arcabio.com/investors
Company Research
Source: GlobeNewswire
WESTMINSTER, Colo., Sept. 11, 2019 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today announced that Gencaro atrial fibrillation clinical data from the GENETIC-AF Phase 2B trial have been selected for presentation at the Heart Failure Society of America (HFSA) 2019 Annual Scientific Meeting being held September 13-16 in Philadelphia. William T. Abraham, MD, FACP, FACC, College of Medicine Distinguished Professor, Division of Cardiovascular Medicine at The Ohio State University Wexner Medical Center, will present the data. “Bucindolol response appears to be greater in heart failure patients with less severe left ventricular dysfunction, a patient population with few therapeutic options for AF prevention or heart failure,” commented Dr. Abraham, “These data provide additional support for pharmacogenetic guided therapy with bucindolo
Show less
Read more
Impact Snapshot
Event Time:
ABIO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ABIO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ABIO alerts
High impacting ARCA biopharma, Inc. news events
Weekly update
A roundup of the hottest topics
ABIO
News
- ARCA biopharma, Inc. (NASDAQ: ABIO) was upgraded by analysts at StockNews.com to a "sell" rating.MarketBeat
- Upcoming Stock Splits This Week (September 2 to September 6) – Stay Invested [Yahoo! Finance]Yahoo! Finance
- ARCA biopharma Announces Completion of Merger with Oruka Therapeutics and Implementation of Reverse Stock Split [Yahoo! Finance]Yahoo! Finance
- ARCA biopharma Announces Completion of Merger with Oruka Therapeutics and Implementation of Reverse Stock SplitGlobeNewswire
- ARCA biopharma Provides Update Regarding Special Dividend Amount in Connection with the Proposed Merger with Oruka TherapeuticsGlobeNewswire
ABIO
Sec Filings
- 8/30/24 - Form 4
- 8/27/24 - Form SEC
- 8/27/24 - Form SEC
- ABIO's page on the SEC website